Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor

被引:146
作者
Knowlden, JM [1 ]
Hutcheson, IR [1 ]
Barrow, D [1 ]
Gee, JMW [1 ]
Nicholson, RI [1 ]
机构
[1] Cardiff Univ, Tenovus Ctr Canc Res, Welsh Sch Pharm, Cardiff CF10 3XF, S Glam, Wales
关键词
D O I
10.1210/en.2005-0247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is considerable evidence that the epidermal growth factor receptor (EGFR) and IGF-I receptor (IGF-IR) cross-talk in breast cancer cells. In the present study, we have examined whether EGFR/IGF-IR cross-talk exists in EGFR-positive tamoxifen-resistant variants of MCF-7 (Tam-R) and T47D (T47D-R) breast cancer cell lines. Although Tam-R cells expressed reduced IGF-IR protein levels compared with their wild-type MCF-7 counterparts, phosphorylated IGF-IR protein\ levels were equivalent in the two cell lines under basal growth conditions, possibly as a consequence of increased IGF-II expression in Tam-R cells. IGF-II activated both IGF-IR and EGFR in Tam-R cells, whereas only activation of IGF-IR was observed in wild-type cells. In contrast, epidermal growth factor rapidly induced EGFR, but not IGF-IR, phosphorylation in Tam-R cells. IGF-II promoted direct association of cSRC with IGF-IR, phosphorylated c-SRC, and increased EGFR phosphorylation at tyrosine 845, a c-SRC-dependent phosphorylation site. Pretreatment with either AG1024 (IGF-IR-specific inhibitor) or an IGF-II neutralizing antibody inhibited basal IGF-IR, c-SRC, and EGFR phosphorylation, and AG1024 significantly reduced Tam-R basal cell growth. The c-SRC inhibitor SU6656 also inhibited growth, reduced basal and IGF-II-induced c-SRC and EGFR phosphorylation, and blocked EGFR activation by TGF alpha. Similarly, in T47D-R cells, AG1024 and SU6656 inhibited basal and IGF-II-induced phosphorylation of c-SRC and EGFR, and SU6656 reduced TGF alpha-induced EGFR activity. These results suggest the existence of a unidirectional IGF-IR/EGFR cross- talk mechanism whereby IGF-II, acting through the IGF-IR, regulates basal and ligand-activated EGFR signaling and cell proliferation in a c-SRC-dependent manner in Tam- R cells. This cross- talk between IGF-IR and EGFR is not unique to Tam- R cells because this mechanism is also active in a tamoxifen-resistant T47D-R cell line.
引用
收藏
页码:4609 / 4618
页数:10
相关论文
共 48 条
[1]   The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase [J].
Ahmad, T ;
Farnie, G ;
Bundred, NJ ;
Anderson, NG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (03) :1713-1719
[2]   Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells [J].
Balañá, ME ;
Labriola, L ;
Salatino, M ;
Movsichoff, F ;
Peters, G ;
Charreau, EH ;
Elizalde, PV .
ONCOGENE, 2001, 20 (01) :34-47
[3]   ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].
BENZ, CC ;
SCOTT, GK ;
SARUP, JC ;
JOHNSON, RM ;
TRIPATHY, D ;
CORONADO, E ;
SHEPARD, HM ;
OSBORNE, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95
[4]   c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function [J].
Biscardi, JS ;
Maa, MC ;
Tice, DA ;
Cox, ME ;
Leu, TH ;
Parsons, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) :8335-8343
[5]   SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling [J].
Blake, RA ;
Broome, MA ;
Liu, XD ;
Wu, JM ;
Gishizky, M ;
Sun, L ;
Courtneidge, SA .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (23) :9018-9027
[6]   Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Iα [J].
Brockdorff, BL ;
Heiberg, I ;
Lykkesfeldt, AE .
ENDOCRINE-RELATED CANCER, 2003, 10 (04) :579-590
[7]   Inhibition of the type 1 insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy [J].
Brodt, P ;
Samani, A ;
Navab, R .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1101-1107
[8]   Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor [J].
Burgaud, JL ;
Baserga, R .
EXPERIMENTAL CELL RESEARCH, 1996, 223 (02) :412-419
[9]   A FUNCTIONAL INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR IS REQUIRED FOR THE MITOGENIC AND TRANSFORMING ACTIVITIES OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR [J].
COPPOLA, D ;
FERBER, A ;
MIURA, M ;
SELL, C ;
DAMBROSIO, C ;
RUBIN, R ;
BASERGA, R .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (07) :4588-4595
[10]  
CULLEN KJ, 1990, CANCER RES, V50, P48